Efficacy and toxicity of pegylated liposomal doxorubicin-based chemotherapy in early-stage breast cancer: a multicenter retrospective case-control study.

Autor: Yang FO; Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan., Hsu NC; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan., Moi SH; Breast Cancer Society of Taiwan, Taipei, Taiwan., Lu YC; Department of Hematology-Oncology, Ditmanson Medical Foundation, Chia-Yi Christian Hospital, Chiayi, Taiwan., Hsieh CM; Breast Center, Taiwan Adventist Hospital, Taipei, Taiwan., Chang KJ; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan., Chen DR; Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan., Tu CW; Department of Surgery, Chiayi Christian Hospital, Chiayi, Taiwan., Wang HC; Department of Surgery, China Medical University Hospital, Taichung, Taiwan., Hou MF; Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.; Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.; Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan.
Jazyk: angličtina
Zdroj: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2018 Jun; Vol. 14 (3), pp. 198-203. Date of Electronic Publication: 2017 Oct 18.
DOI: 10.1111/ajco.12771
Abstrakt: Aim: PEGylated liposomal doxorubicin (PLD) has comparable efficacy and differing toxicity from conventional anthracyclines used to treat advanced breast cancer. This study compared disease-free survival and toxicity between PLD-based and conventional anthracycline-based regimens as adjuvant treatments for early-stage breast cancer.
Methods: We analyzed disease-free survival (DFS) rates, and adverse events in 102 women with early-stage (I-IIIa) breast cancer who received adjuvant PLD-based chemotherapy from 2002 to 2008. Each patient was matched for age, stage at diagnosis, HER-2 expression and hormone therapy use to a patient treated with an epirubicin-based regimen. Fisher's exact and Pearson's chi-square tests were used for categorical data analysis. Kaplan-Meier analysis and Cox regression models were used to analyze DFS.
Results: DFS at 5 years was 81.3% for PLD-based regimen and 82.3% for epirubicin-based regimen. This difference was not significant (p = 0.939). Stage IIIa disease was associated with a shorter DFS in univariate analysis (p = 0.048). In multivariate analysis that controlled for adjuvant treatment, age at diagnosis, stage, HER-2 expression, type of surgery and hormone and radiation therapy, stage IIIa disease (P = 0.023) and lack of hormone therapy (P = 0.024) were each independently associated with shorter DFS. Adverse events were evaluated, and with the exception of hand-foot syndrome, more grade 3 and 4 toxicities occurred in patients who received epirubicin-based regimens than in those given PLD-based regimens.
Conclusion: For patients with early-stage breast cancer who received PLD-based adjuvant chemotherapy, 5-year DFS was comparable and toxicity was acceptable, yet different from those of patients who received epirubicin-based regimens.
(© 2017 John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje